Key result
Baseline MCP-1 demonstrated better diagnostic accuracy for AMI at 0-6 hours after chest pain onset compared to cTnI, though cTnI was superior at >12-24 hours.
Why the study?
This study aimed to assess the diagnostic performance of monocyte chemoattractant protein-1 (MCP-1) for the early diagnosis of acute myocardial infarction among patients presenting with chest pain.
Does MCP-1 measurement improve the early diagnosis of acute myocardial infarction compared to cardiac Troponin I in patients presenting with chest pain?
Observational
Does MCP-1 measurement improve the early diagnosis of acute myocardial infarction compared to cardiac Troponin I in patients presenting with chest pain?
MCP-1 may offer better early diagnostic accuracy (0-12 hours) for acute myocardial infarction than cardiac Troponin I, though Troponin I remains superior after 12 hours.
Answers are grounded in this paper and cite their sources.
MCP-1 may support early AMI diagnosis in chest pain; leaves open incremental value over troponin in prospective studies.
Background: Acute myocardial infarction (AMI) controlled and promoted by inflammation within the coronary plaque. Monocyte chemoattractant protein-1 (MCP-1) is a pro-inflammatory mediator, that’s playing a major role in plaque rupture. This study aimed to assess the diagnostic performance of MCP-1 for early diagnosis of AMI among chest pain (CP) patients. Methods: MCP-1 and cardiac Troponin I (cTnI) were performed for all studied patients. The receiver operating characteristic (ROC) curve was used to assess the diagnostic accuracy of biomarkers. Results: The baseline level of MCP-1 has a good capacity for discriminating patients with AMI from non-coronary chest pain (NCCP), stable angina (SA), and unstable angina (UA) patients with efficiency 91%, 91%, and 83%; respectively. Area under the curves (AUCs) of MCP-1 for diagnosis AMI patients at 0-6 hours and > 6-12 hours after onset time of CP were 0.69 (P < 0.001); and 0.71(P < 0.0001); respectively, compared with cTnI were 0.58 (P < 0.001) and 0.67 (P < 0.001); respectively. However, at > 12-24 hours, cTnI has AUC 0.93 (P < 0.0001) compared with MCP-1 0.74 (P < 0.0001). conclusion: Independent early baseline MCP-1 has given sufficient diagnostic information for patients with AMI.
No takes yet. Share an insight, caveat, or question.
Omran et al. (2019) conducted an observational in Acute myocardial infarction. Monocyte chemoattractant protein-1 (MCP-1) vs. Cardiac Troponin I (cTnI) was evaluated on Diagnosis of AMI at 0-6 hours after onset of chest pain (AUC 0.69, p=<0.001). Baseline MCP-1 demonstrated better diagnostic accuracy for AMI at 0-6 hours after chest pain onset compared to cTnI, though cTnI was superior at >12-24 hours.
Synapse has enriched 10 related papers. Consider them for comparative context: